BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products
Posted on: Tuesday, 7 April 2009, 14:39 CDT
The report is scheduled to release at the end of April, and is available at pre-release pricing until
Scientists involved in stem cell research, whether they are more focused on understanding basic stem cell biology, developing cell-based therapies using stem cells, or using stem cells to improve drug target validation and toxicology screening, rely on stem cell research products from major life science suppliers as well as more niche stem cell companies. In this report, scientists specify percentage of stem cell culture products purchased from each of the following suppliers:
ATCC BD Biosciences (a part of Becton, Dickinson and Co., NYSE: BDX) CellGenix Life Technologies (Nasdaq: LIFE) Lonza (SWX: LONN) Millipore (NYSE: MIL) Miltenyi Biotec R&D Systems (division of TECHNE Corp., Nasdaq: TECH) Sigma-Aldrich (divisions: SAFC Biosciences, Nasdaq: SIAL) Stem Cell Sciences (AIM: STEM) Stemcell Technologies Thermo Fisher Scientific (Hyclone, NYSE: TMO) Zen BioLife science suppliers can use this study to determine areas poised for growth (i.e., media, sera, supplements and cell lines) in the stem cell research products market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure a leading position in this expanding market. The report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers.
"There is tremendous excitement, especially in the academic community, over the recent Executive Order signed by President
To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/201/.
ABOUT BIOINFORMATICS, LLC
BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 42,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
For more information contact: Mary Follin Manager, Marketing/Sales BioInformatics, LLC 2111 Wilson Blvd., Suite 250 Arlington, VA 22201 703.778.3080 x13 (phone) m.follin@gene2drug.com http://www.gene2drug.com/SOURCE BioInformatics, LLC
Source: PR Newswire
Related Articles
- BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
- Bauer Calls Taxpayer-Funded Embryonic Stem Cell Research 'A Tragedy'
- Research and Markets: FPL Energy, LLC Wind Power Portfolio Analysis Provides Analysis of FPL Energy's Key Revenue Lines
- Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created By a Heart Attack
- Research and Markets: Renewing the Stuff of Life Stem Cells Ethics and Public Policy is Both a Primer and a Means By Which to Understand the Implications of This Complex Subject
- A Market Insight into the Progressing and Debatable Market of Stem Cell Research
- Consumer Advocates Praise Congress for Approving Stem Cell Research Funding Bill, Say Scientific Breakthrough on Cell Derivation Underscores Need For More Research
- Invitrogen Partners With Cytori to Offer Adipose Stem Cell Research Products
- Christian Defense Coalition: Frist Can No Longer Consider Himself Pro-Life & Vote to Expand Funding for Embryonic Stem Cell Research
- Chemicon International, Inc. Enters into a License to Commercialize Research Products Utilizing Human Embryonic Stem Cell Technology From Wisconsin Alumni Research Foundation (WARF)
 |
 |
User Comments (0)
RSS Feeds